Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

By S. Boekholdt, B. Arsenault, S. Mora, T. Pedersen, J. Larosa, P. Nestel, R. Simes, P. Durrington, G. Hitman, K. Welch and 9 more. Journal of the American Medical Association (JAMA), 2012

749 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/76880db1a288562fc8e2279a81a2c5c5a5c61ba6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Surgery

Citations in the corpus

2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, neutral): “There is evidence for a role of non-HDL-C as a treatment target [364].”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “There is evidence for a role of non-HDL-C as a treatment target.(364) Since non-HDL-C is capturing the information”
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. (2015, methodology): “When triglycerides are between 200 and 499 mg/dL, the targets of therapy are non–HDL-C and LDL-C.”
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, background): “Notably, in the statin trials, the absolute yearly event rate observed in each randomized treatment arm was strongly and linearly associated with the absolute achieved LDL-C level (Figure 5A).(34) In these studies, LDL-C and apoB concentrations had very similar effects on the risk of cardiovascular ”
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Page 38 of 71 Recommend early revascularization for cardiogenic shock due to cardiac pump failure I B (291, 293, 294) DM Recommend medical treatment and decisions for testing and revascularization similar to those for patients without DM I A (173, 176, 295) Post–CABG Recommend GDMT antiplatelet and ”
Hyperlipidemia as a Risk Factor for Cardiovascular Disease (2012, background): “In a meta-analysis of 38,153 statin treated subjects in whom nonHDL-C, LDL-C and Apo-B were compared, all three markers were predictive of CVD, with non-HDL-C showing a slightly greater association than the other two (18).”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “There is evidence for a role of non-HDL-C as a treatment target.(364) Since non-HDL-C is capturing the information”
Dyslipidemia in Obesity: Mechanisms and Potential Targets (2013, background): “Although others did not describe any benefit of apo B or non-HDL-C over LDL-C levels to assess cardiovascular risk [140–142].”